Combined drug design of potential Mycobacterium tuberculosis and HIV-1 inhibitors: 3’,4’-di-substituted -4'H-spiro[isothiochromene-3,5'-isoxazol]-4(1H)-one

Abstract

We report herein the design and synthesis of 17 new spiroheterocycles 10-26, on the basis of two hypothetical pharmacophore structures designed to interact with both of Mycobacterium tuberculosis bacteria and HIV-1 virus. The in vitro biological evaluation of these compounds allowed us to point out seven new potential non-nucleoside hits, with MIC values in the range of 6.25 g/mL and two new potential anti-HIV-1 inhibitors .